Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Oct 1.

Published in final edited form as: J Neurovirol. 2011 Jul 23;17(5):438–447. doi: 10.1007/s13365-011-0044-3

Table 3. MND and HAD for Evaluable Patients at Week 0, Stratified by Country.

			Country
		Total (N=860)	Brazil (N=161)	India (N=184)	Malawi (N=133)	Peru (N=62)	South Africa (N=167)	Thailand (N=73)	Zimbabwe (N=80)
MND (p-value^*<0.001)	Yes	51 (6%)	18 (11%)	5 (3%)	10 (8%)	1 (2%)	6 (4%)	0 (0%)	11 (14%)
	No	783 (91%)	142 (88%)	155 (84%)	123 (92%)	61 (98%)	160 (96%)	73 (100%)	69 (86%)
	Did not assess	1 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	Missing	25 (3%)	0 (0%)	24 (13%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)

HAD (p-value^*=0.014)	Yes	4 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (3%)
	No	830 (97%)	159 (99%)	159 (86%)	133(100%)	62 (100%)	166 (99%)	73 (100%)	78 (98%)
	Did not assess	1 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	Missing	25 (3%)	0 (0%)	24 (13%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)

^*

Monte Carlo estimate of the exact p-value